image: Researchers illustrate how portal hypertension and splanchnic vasodilation trigger hormonal responses, inflammation, and sodium and water retention, contributing to ascites in decompensated cirrhosis.
Credit: Professor Paolo Caraceni from University of Bologna, Italy | Image Source Link: https://doi.org/10.1002/poh2.70070
Ascites is the most common complication of cirrhosis and often marks the shift from compensated to decompensated disease. It can reduce quality of life, prompt hospitalizations, and increase the risk of infections and kidney complications. Five-year survival falls from about 80% to 30% after clinically significant ascites develops. Treatment therefore aims to control fluid buildup while preventing complications and preserving kidney and circulatory function.
Addressing this challenge, the research team was led by Professor Paolo Caraceni, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Italy. In this narrative review, the authors examined relevant studies identified through PubMed from its inception to June 2026, alongside findings presented at major international congresses. They assessed human albumin use across clinical settings, distinguishing short-term treatment for acute complications from regular infusions intended to improve longer-term ascites control. The study was published online in the journal Portal Hypertension & Cirrhosis on November 13, 2026.
Albumin is a blood protein used to expand plasma volume and counteract reduced effective circulating blood volume. It may also support blood-vessel function and modulate inflammation. The review describes three established short-term settings: after large-volume paracentesis; during spontaneous bacterial peritonitis; and in acute kidney injury, including hepatorenal syndrome. For removal of more than 5 L of fluid, international guidelines generally recommend 6–8 g of albumin per liter removed.
Albumin use in kidney injury remains debated. A 2024 joint consensus advised volume resuscitation when clinically indicated rather than routinely. Subsequent studies suggest some patients respond only on the second day, while excessive fluid administration may increase the risk of respiratory complications. The review emphasizes tailoring dose and duration to the patient's condition and stopping treatment if fluid overload develops.
For longer-term treatment, evidence is promising but inconsistent. In the ANSWER trial, 431 patients with uncomplicated grade 2 or 3 ascites received standard treatment alone or with albumin: 40 g twice weekly for 2 weeks, then 40 g weekly for up to 18 months. The albumin group had higher 18-month survival and a 38% reduction in mortality risk, alongside fewer paracenteses and complications. By contrast, the MACHT trial found no significant benefit, but used a lower dose and the treatment was often shorter. Studies from Italy, Australia, and India add evidence, while PRECIOSA did not meet its primary endpoint of improved 1-year transplant-free survival.
“Albumin should not be viewed as a universal treatment for every person with cirrhosis and ascites,” says Prof. Caraceni. “The evidence points to benefits in specific situations, but the patient's clinical condition, treatment schedule, and response all matter.”
The review also discusses preliminary evidence that albumin may help some patients with hypervolemic hyponatremia, although larger studies are needed. Better ways to identify likely responders, including biomarker-based approaches, could help guide treatment. This may support more personalized treatment strategies and help health systems assess cost-effectiveness, logistical barriers, and delivery options such as home infusions.
“Ultimately, we need to move beyond a one-size-fits-all approach and match albumin treatment to the patient's needs and goals,” says Prof. Caraceni.
Overall, the review concludes that albumin remains an important option for managing cirrhosis-related ascites, but its value depends on selecting appropriate patients and individualizing treatment. Better evidence on who benefits, at what dose, and for how long will be essential to improve care and guide wider use.
***
Reference
Titles of original paper: Albumin for Treatment of Ascites in Patients With Cirrhosis
Journal: Portal Hypertension & Cirrhosis
DOI: https://doi.org/10.1002/poh2.70075
About University of Bologna, Italy
University of Bologna, founded in 1088, is considered the oldest university in the Western world. Located in Italy, it has a long-standing academic tradition and a strong commitment to teaching, research and engagement with society. Its academic community includes students, teaching staff, researchers and professional personnel across five campuses: Bologna, Cesena, Forlì, Ravenna and Rimini. The university promotes scientific progress, innovation and collaboration with local and international partners. With a broad catalogue of degree programmes, doctoral programmes and postgraduate courses, it aims to contribute to sustainable and inclusive development while making knowledge accessible and beneficial to society.
Website: https://www.unibo.it/en
About Professor Paolo Caraceni
Prof. Paolo Caraceni is a Full Professor in Internal Medicine at the Alma Mater Studiorum University of Bologna in Italy, where he also serves as the Director of the Postgraduate School of Sports Medicine and Physical Exercise. An internationally recognized hepatologist, he is a Member of the Scientific Advisory Board of the European Foundation Chronic Liver Failure Consortium. With an extensive publication record of 296 papers in international journals with impact factors, Prof. Caraceni’s specialized clinical and academic research focuses heavily on advancing medical treatments for liver cirrhosis, acute on chronic liver failure, and human albumin therapy worldwide.
Journal
Portal Hypertension & Cirrhosis
Method of Research
Literature review
Subject of Research
Not applicable
Article Title
Albumin for Treatment of Ascites in Patients With Cirrhosis
Article Publication Date
13-Nov-2026
COI Statement
Giacomo Zaccherini: Octapharma SA (speaking bureau). Paolo Caraceni: Grifols SA (speaking bureau and advisory board), Octapharma SA (speaking bureau), CSL Behring (speaking bureau), Takeda (speaking bureau), Alfasigma (speaking bureau), and Bausch Health (advisory board). The other authors declare no conflicts of interest.